Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244724 · ClinicalTrials.gov registry record · Phase 4
Lexapro for Major Depression in Patients With Epilepsy
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT01244724 is a Phase 4 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 26 participants.
The verdict
NCT01244724, a Phase 4 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The primary objective will be to pilot the use of escitalopram for the treatment of major depression in patients with epilepsy. The secondary objectives will be to determine effect sizes on scales measuring depressive symptoms, physical symptoms, psychosocial function and quality of life, and to evaluate safety in the population of patients with epilepsy. These results will be used to evaluate the possibility of a future double-blind, placebo controlled RCT of escitalopram for the treatment of major depression in patients with epilepsy.
Interventions
- DRUG Lexapro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01244724
The ClinicalTrials.gov registry entry for NCT01244724 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lexapro is the first listed.
NCT01244724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01244724 about?
NCT01244724 is a clinical study titled "Lexapro for Major Depression in Patients With Epilepsy". The primary objective will be to pilot the use of escitalopram for the treatment of major depression in patients with epilepsy. The secondary objectives will be to determine effect sizes on scales measuring depressive symptoms, physical symptoms, psychosocial function and quality of life, and to eva...
What is the current status of trial NCT01244724?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2007-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01244724?
The interventions under investigation include: Lexapro (DRUG).
Who is sponsoring clinical trial NCT01244724?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.